Swiss global healthcare firm Roche has introduced new viral load monitoring assays, cobas HIV-1 and cobas HCV assays, for use on the cobas 6800 / 8800 systems.

The new assays allows clinicians to manage the treatment of patients infected with human immunodeficiency virus (HIV-1) or hepatitis C (HCV).

According to Roche, in the next few months the new assays will be followed by cobas CMV and cobas HBV assays, which will complete the primary portfolio of viral load monitoring assays for the cobas 6800 / 8800 Systems.

The viral load portfolio on the cobas 6800 / 8800 systems will improve productivity in laboratories and help deliver results for rapid clinical decisions.

Roche Diagnostics chief operating officer Roland Diggelmann said: "The cobas 6800 / 8800 Systems represent the next generation of molecular diagnostic instruments that offer unparalleled performance, unmatched flexibility and absolute automation.

"The viral load portfolio on cobas 6800 / 8800 systems will provide laboratories with improved productivity and the ability to deliver results for rapid clinical decisions."

"By virtue of their design and clinical utility, the cobas HIV-1 and cobas HCV tests set new industry standards for viral load assays, delivering on Roche’s commitment to provide new diagnostic tools to advance the medical community’s understanding about viral disease and improve the ability to treat patients."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Viral load testing assays for new molecular diagnostic platforms are available in all countries accepting CE Mark, and are not currently available in the US.

Cobas 6800 and 8800 systems are available in medium and high throughput models, and are fully automated solutions developed for blood donor screening, viral load monitoring, women’s health and microbiology testing.

Based on PCR technology, the systems are designed to deliver increased automation and throughput with shorter time to results, providing users with greater testing flexibility to increase overall workflow efficiencies.